Netflix Down, SpaceX Up: Upside/Downside Movers in the A.M.

Avatar photo Doug Kass on October 21, 2026

Upside

– $SMCI +12% (preliminary fiscal Q1 revenue outlook was raised well above expectations, with gross-margin upside)

– $SPCX +8.2% (Q3 revenue and profit crushed expectations, marking its first quarterly profit since the IPO, while special committees evaluate a potential TSLA merger)

– $CRDO +7.2%, $VRT +6.7%, $DELL +6.9%, $LITE +5.6%, $HPE +5.0%, $COHR +4.6% (AI-infrastructure suppliers rise as the SMCI outlook and SPCX AI-compute results reinforce data-center demand)

– $WDC +4.0%, $SKHY +3.7%, $SNDK +3.7%, $STX +3.6%, $MU +3.1% (memory and storage names gain on the stronger AI-infrastructure demand read-through)

– $APLD +4.0% (Texas AI data-center agreement and bullish analyst action)

– $INTC +2.3%, AMD +2.1%, $NVDA +2.0% (chip stocks rise as strong AI-compute and server demand updates lift the broader complex)

– $TSLA +1.4% (special committee formed with SPCX to evaluate a potential merger ahead of earnings)

Downside

– $TKNO -30% ($40M primary offering priced at $5 per share, a steep discount to the prior close)

– $NFLX -7.0% (Q3 profit beat, but the Q4 sales outlook missed and the 2026 advertising-revenue forecast was cut to $2.7B from $3B)

– $ISRG -6.7% (Q3 beat, but U.S. procedure growth slowed, instrument pricing reductions were outlined and the high end of the procedure-growth outlook was cut)

– $T -5.6% (Q3 beat and FY EPS guidance was raised, but postpaid phone additions missed expectations amid satellite-competition concerns)

– $DHR -3.6% (Q3 beat and FY EPS guidance was raised, but the Q4 core-growth outlook remained modest with a respiratory-revenue headwind)

– $TMO -3.0% (sell-the-news reaction after a Q3 beat and raised FY guidance)

– $ACN -1.5% (Baird downgrades to Neutral from Outperform on valuation and slower organic growth)

Select Premarket Movers

Avatar photo Doug Kass on October 14, 2026

Upside

– $LQDA +41.0% ($380.7M global settlement resolves six lawsuits and preserves uninterrupted YUTREPIA commercialization)

– $TCRT +25.5% (completed Velaris acquisition and secured an approximately $350M private placement to fund development through 2029)

– $VSTM +11.0% (VS-7375 produced a 50% confirmed response rate in eight second-line pancreatic-cancer patients, with FDA alignment on a Phase 3 plan)

– $ENVX +10.0% (received a 100,000-battery drone order and reported preliminary Q3 revenue above guidance)

– $BLK +5.0% (Q3 beat as $205B of net inflows and strong organic base-fee growth topped expectations)

– $ACN +4.0% (investor day targets)

Downside

– $BMEA -20.0% (Phase 1 BMF-650 weight-loss data disappointed investors despite no severe or serious treatment-emergent events)

– $STT -8.5% (Q3 EPS was roughly in line, but revenue missed and fee revenue declined sequentially)

– $FAST -4.5% (Q3 revenue came in slightly light and the 2026 device-signings target was trimmed despite an EPS beat and better operating margin)

– $BAC -4.5% (Q3 adjusted EPS and revenue missed as a $1.2B regulatory-settlement charge weighed on results)

– $HPE -4.5%, NTAP -4.0%, DELL -3.0% (Barclays downgrades the hardware names to Equal Weight, citing valuation and a lack of meaningful AI-driven growth inflection)

– $CRWV -4.0% (no clear fresh company-specific catalyst identified; unusually large premarket move)

Position: None

Upside, Downside Movers in the Morning

Avatar photo Doug Kass on October 8, 2026

Upside

– $PROF +19% (preliminary Q3 revenue was about 45%-47% above consensus, with gross margin expected above 70%)

– $HAE +14% (no fresh company catalyst confirmed; unusually large move on light premarket volume)

– $WOLF +13% (received a conditional commitment for up to $1.5B of 30-year U.S. defense financing, partly offset by warrants for up to 7.5% of diluted equity)

– $EFX +4.5% (no fresh company catalyst confirmed; unusually large premarket move)

– $APA +3.1%, OXY +2.5%, DVN +2.4% (oil producers rise as WTI and Brent jump roughly 4.5%)

– $PLTR +2.3% (extends AI-software momentum despite weaker index futures)

– $PEP +1.6% (Q3 revenue and profit beat expectations; a better-than-feared quarter offsets a cut to the FY earnings-growth outlook)

Downside

– $ARGX -15% (Phase 3 UNITY study in Sjögren’s disease was stopped for futility, overshadowing positive Phase 2 celiac-disease data)

– $GLW -3.3% (no fresh company catalyst confirmed; unusually large premarket move)

– $EQIX -3.0% (rate-sensitive data-center REIT falls as the 10-year Treasury yield climbs to roughly 5.33%)

– $NXPI -3.1%, $AMAT -2.5%, $LRCX -2.9%, $HPE -2.0% (semiconductor and hardware names weaken as Treasury yields rise and global technology shares sell off)

– $SHW -2.7% (crude-oil surge raises petrochemical feedstock and input-cost concerns)

Upside, Downside Movers in the Morning

Avatar photo Doug Kass on September 30, 2026

Upside

– $CNTB +83% (Phase 2 COPD trial met its primary endpoint, reducing treatment failures by 81% and new moderate-to-severe exacerbations by 85%)

– $NAUT +16% (no clear fresh catalyst identified; unusually large, liquid premarket move)

– $CAPR +14% (new deramiocel analyses showed slower upper-limb decline in the HOPE-3 open-label extension and versus natural history)

– $BIYA +13% (first-half results showed new continuing-operations revenue and a narrower net loss)

– $SGMT +9.0% (rises ahead of today’s KOL event on 52-week Phase 3 extension data and the planned US AURORA Phase 3 trial)

– $KALA +5.3% (signs a non-binding agreement to acquire a nationwide telehealth platform for approximately $15M)

– $HPE +4.2% (no clear fresh catalyst identified; unusually large premarket move in a major liquid stock)

Downside

– $PYXS -16% (prices a public offering of up to $282.6M, adding substantial dilution and stock supply)

– $SDEV -15% (pulls back after the prior session’s outsized speculative surge)

– $CNXC -8.7% (quarterly profitability topped guidance, but Q4 sales and profit guidance came in light and the FY revenue outlook missed expectations)